IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

Higher development and administrative spending accompanied a wider quarterly loss, while cash runway guidance remained unchanged into 2030.

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) reported a third-quarter net loss of $125.7 million while completing its first darovasertib approval application. Collaboration revenue rose to $10.2 million from $8.9 million in the second quarter, while the net loss widened from $112.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.15 billion at September 30, down from $1.24 billion at June 30; the company maintained cash runway guidance into 2030.

The FDA application seeks approval of darovasertib plus crizotinib for metastatic uveal melanoma. Enrollment challenges prompted closure of Phase 3 OptimUM-010; IDEAYA expects estimated savings of $100-125 million for other pipeline programs. A separate adjuvant Phase 3 trial has begun. IDEAYA plans two IDE849 Phase 3 trials by year end and expects initial global Phase 1/2 data by the end of 2026 or early 2027.

23 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointDarovasertib plus crizotinib FDA application completed in Q3 2026 for potential metastatic uveal melanoma approval.
• Moderate pointCollaboration revenue rose to $10.2 million in Q3 2026 from $8.9 million in Q2 2026.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway guidance into 2030 remains unchanged under the current operating plan.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Estimated $100-125 million savings from OptimUM-010 closure are expected to be reallocated to other pipeline programs. 3.3% of market cap
• Moderate pointOptimUM-02 showed statistically significant progression-free survival improvement versus investigator's choice in untreated HLA-A*02:01-negative metastatic uveal melanoma.
• Moderate pointOptimUM-011 Phase 3 trial initiated with Servier; approximately 450 higher-risk primary uveal melanoma patients expected.
• Moderate pointIDE849 partner Phase 1 trial reported median overall survival of 17.4 months in second-line small cell lung cancer.
• Moderate point. Forward-looking: it has not happened yet and may not happen.IDE849 global Phase 1/2 initial data expected by the end of 2026 or early 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Two IDE849 Phase 3 trials planned by year end in extensive-stage small cell lung cancer and neuroendocrine carcinomas.
• Moderate pointGenentech collaboration signed in August to evaluate IDE892 with RG6620; Genentech will sponsor and conduct the trial.
• Moderate point. Forward-looking: it has not happened yet and may not happen.$139.8 million remaining service obligations relate to anticipated Servier reimbursements, recognizable as revenue as services are completed. 4.6% of market cap
• Moderate pointCash and securities totaled $1,150.827 million at September 30, 2026, versus $1,049.685 million at December 31, 2025.

11 minor points

• Minor pointOptimUM-09 showed tumor shrinkage in >85% of treated patients and 57% eye preservation in the enucleation cohort.
• Minor pointOptimUM-09 plaque brachytherapy cohort: 74-79% achieved reduced predicted radiation doses to critical eye structures.
• Minor pointIDE849 other neuroendocrine carcinomas: response rate 52.6%; confirmed response rate 36.8%, among 19 patients.
• Minor pointIDE849 other neuroendocrine carcinomas: median progression-free survival 7.0 months; nine-month overall survival rate 82.4%.
• Minor pointIDE849 with IDE161 is being evaluated in a Phase 1 combination cohort.
• Minor point. Forward-looking: it has not happened yet and may not happen.IDE034 initial Phase 1 data planned in 2027, including preliminary safety and efficacy results.
• Minor pointIDE892 monotherapy expansion initiated in MTAP-deleted solid tumors at projected efficacious target human exposures.
• Minor point. Forward-looking: it has not happened yet and may not happen.IDE892 with Roche's RG6505 Phase 1 trial initiation targeted by the end of 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.IDE892 with IDE397 Phase 1/2 cohort initiated; expansion planned by the first half of 2027.
• Minor pointIDE574 with fulvestrant first patient dosed in October in a Phase 1 metastatic breast cancer cohort.
• Minor pointInterest and other income, net rose to $11.883 million in Q3 2026 from $9.839 million in Q2.

Negative

• Moderate pointQ3 2026 net loss widened to $125.7 million from $112.5 million in Q2; loss per share remained $1.22.
• Moderate pointOptimUM-010 Phase 3 closure follows ongoing site activation and enrollment challenges.
• Moderate pointNine-month collaboration revenue fell to $25.660 million in 2026 from $207.834 million in 2025.
• Moderate pointNine-month R&D expenses rose to $325.991 million in 2026 from $228.105 million in 2025.
• Minor pointCash and securities fell to approximately $1.15 billion at September 30 from $1.24 billion at June 30.

9 minor points

• Minor pointQ3 2026 R&D expenses increased to $121.6 million from $108.7 million in Q2.
• Minor pointQ3 2026 administrative expenses increased to $26.3 million from $22.5 million in Q2.
• Minor pointNine-month net loss widened to $336.740 million in 2026 from $30.425 million in 2025.
• Minor pointNine-month loss per share increased to $3.56 in 2026 from $0.34 in 2025.
• Minor pointNine-month administrative expenses rose to $68.135 million in 2026 from $44.472 million in 2025.
• Minor pointNine-month interest and other income, net declined to $31.726 million in 2026 from $34.318 million in 2025.
• Minor pointQuarterly weighted-average shares increased to 102,944,175 in Q3 2026 from 92,061,452 in Q2.
• Minor pointNine-month weighted-average shares increased to 94,620,638 in 2026 from 88,452,395 in 2025.
• Minor pointTotal liabilities increased to $123.957 million at September 30, 2026, from $86.390 million at December 31, 2025.

News Explained

At September 30, 2026, IDEAYA reported $139.8 million remaining in Servier-related R&D service performance obligations; it says anticipated clinical-development cost reimbursements will be recognized as collaboration revenue over time as the services are completed.

Key Figures

Cash and marketable securities: $1,150,827 thousand Cash runway guidance: Into 2030 Collaboration revenue: $10,242 thousand +5 more

Cash and marketable securities

$1,150,827 thousand

As of September 30, 2026

Cash runway guidance

Into 2030

Unchanged based on the current operating plan

Collaboration revenue

$10,242 thousand

Three months ended September 30, 2026

Research and development expenses

$121,576 thousand

Q3 2026; versus $108,689 thousand in Q2 2026

Net loss

$125,749 thousand

Three months ended September 30, 2026

Median overall survival

17.4 months

IDE849, 2L SCLC

Objective response rate

52.6% (10/19)

IDE849, other NECs

Confirmed objective response rate

36.8% (7/19)

IDE849, other NECs

Previous Earnings Reports

1 past event · Latest: Aug 04

Same Type 1 event

1. Aug 04

   Quarterly earnings

   24h Move

   +2.0%

   OptimUM-02 met its primary endpoint; NDA filing was underway under FDA real-time review.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

new drug application, real-time oncology review, progression free survival, blinded independent central review, +2 more

6 terms

new drug application regulatory

"submitted a new drug application (NDA) to the U.S. Food and Drug Administration"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

real-time oncology review regulatory

"under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program"

A regulatory process in which reviewers assess clinical data and application materials for a cancer therapy as they are submitted, instead of waiting for a complete package. By allowing questions to be answered and issues resolved during the submission rather than afterward, it can speed up decisions and reduce surprise delays. For investors, that means greater predictability around potential approvals or setbacks and a faster path to a drug reaching the market, similar to editing a book chapter-by-chapter rather than after the whole manuscript is finished.

progression free survival medical

"median progression free survival (PFS) compared to investigator's choice"

Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.

blinded independent central review medical

"as determined by both blinded independent central review (BICR)"

Blinded independent central review is a quality-control step in clinical trials where outside medical experts, who do not know which patients received the experimental therapy, re-examine key measurements (like scans or lab results) to prevent bias. Think of it as neutral referees watching game footage without knowing the teams, which gives investors greater confidence that the trial results are fair, more reliable for regulators, and less likely to be overturned or disputed.

overall survival medical

"including median overall survival (OS) of 17.4 months"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

antibody-drug conjugates medical

"Antibody-drug conjugates (ADCs) IDE849 (DLL3 TOP1 ADC)"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy
• Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma
• Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027
• IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers
• $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

"We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma," said Yujiro S. Hata, Chief Executive Officer of IDEAYA.  "We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.  Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech."

Selected Pipeline Developments and Corporate Updates

Darovasertib for Uveal Melanoma (UM)

• IDEAYA presented clinical data from two ongoing clinical trials in metastatic UM (mUM) at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.  The OptimUM-01 update focused on the Phase 2 expansion results in 101 HLA-A*02:01-positive patients, including both treatment naïve and 2L patients who received prior tebentafusp.  The OptimUM-02 update builds on positive topline data reported in June showing treatment naïve HLA-A*02:01-negative patients receiving darovasertib plus crizotinib (the darovasertib combination) had a meaningful and statistically significant improvement in median progression free survival (PFS) compared to investigator's choice of therapy as determined by both blinded independent central review (BICR) and investigator assessment.  Collectively, the data support the broad potential of the darovasertib combination to drive meaningful clinical benefits for patients with mUM, irrespective of HLA-A*02:01 allele status or line of therapy.
• During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program.
• In primary UM, IDEAYA provided follow-up data at ESMO 2026 from approximately 119 patients enrolled in the Phase 2 OptimUM-09 trial evaluating single-agent darovasertib as a neoadjuvant therapy.  Consistent with prior results, >85% of patients treated with darovasertib experienced robust tumor shrinkage, resulting in a 57% eye preservation rate in the enucleation cohort and 74-79% of patients in the plaque brachytherapy cohort achieving a reduced predicted dose of radiation to critical eye structures including the fovea, disc center and lens.   
• Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial. This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892.
  • IDEAYA is committed to enabling patient access to neoadjuvant darovasertib and plans to submit published data from OptimUM-09 to support potential inclusion in clinical practice guidelines.  If successful, guideline inclusion is intended to provide evidence to support the potential clinical benefit of neoadjuvant darovasertib and may allow payor coverage for eligible patients in the United States. 
• Following completion of a Type C meeting with the FDA earlier this year, IDEAYA and its partner, Les Laboratoires Servier (Servier), initiated a global Phase 3 registrational trial (OptimUM-011) to evaluate the darovasertib combination in the adjuvant setting of primary uveal melanoma. The trial is expected to enroll approximately 450 patients with increased risk of metastasis, irrespective of HLA status, randomized 1:1 to either 12-months of treatment with the combination or observation.  The primary endpoint of the trial is relapse-free survival.

Antibody-drug conjugates (ADCs)

• IDE849 (DLL3 TOP1 ADC): IDEAYA's partner, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), provided a clinical update at ESMO 2026 from its Phase 1 trial in China evaluating IDE849 in patients with relapsed SCLC and NEC.  The data showed substantial anti-tumor activity together with more mature PFS results and encouraging survival outcomes, including median overall survival (OS) of 17.4 months in the 2L SCLC setting. The update also included data from 19 patients with other NECs, showing an ORR and confirmed ORR of 52.6% (10/19; 95% CI: 28.9–75.6) and 36.8% (7/19; 95% CI: 16.3–61.6), respectively, a median PFS of 7.0 months and nine-month OS rate of 82.4%.  IDEAYA plans to provide the first clinical data from its global Phase 1/2 trial of IDE849 monotherapy in extensive-stage SCLC (ES-SCLC) and NEC by the end of 2026 or early in 2027.
  • Following successful Type C meetings with the U.S. FDA, IDEAYA plans to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by year end.
  • The ES-SCLC trial will enroll 400 patients with prior tarlatamab treatment, randomized 1:1 to IDE849 or investigator's choice of therapy. The primary endpoint for accelerated approval will be ORR by BICR, and median OS for full approval. Secondary endpoints will include median DOR by BICR, PFS, and safety.  Details of the design of the Phase 3 trial in NEC will be provided at a later date.
• IDE161 (PARG): IDEAYA is also evaluating a Phase 1 combination cohort of IDE849 with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor in patients with ES-SCLC, NEC and other DLL3-overexpressing solid tumors.  IDEAYA has previously shared preclinical data demonstrating the mechanism of action of IDE161 in combination with TOP1-payload based ADCs in driving enhanced anti-tumor activity.
• IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data.  IDE034 is a potentially first-in-class B7H3/PTK7 bispecific TOP1 ADC designed to be internalized only when its target antigens are co-expressed on the same tumor cell, which may enhance its selectivity and tolerability profile relative to monovalent antibody formats.

MTAP pathway

• IDE892 (PRMT5): monotherapy expansion has been initiated in the Phase 1 clinical trial evaluating IDE892 in MTAP-deleted solid tumors, with a focus on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).  The expansion has been initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved.  The IDE892 maximum tolerated dose has not yet been reached in the ongoing dose escalation.  Pursuant to the clinical collaboration announced with Roche in May, IDEAYA is also targeting initiation of a Phase 1 trial to evaluate IDE892 in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant PDAC by the end of 2026.
  • In August, IDEAYA entered into a Clinical Supply Collaboration Agreement with Genentech to evaluate IDE892 in combination with RG6620, a Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant PDAC.  Genentech will sponsor and conduct the trial and IDEAYA will provide clinical supply of IDE892.
• IDE397 (MAT2A): a Phase 1/2 combination cohort was initiated to evaluate IDE892 with IDE397, IDEAYA's proprietary MAT2A inhibitor, in MTAP-deleted cancers.  Expansion is planned by the first half of 2027 with an initial clinical focus on MTAP-deleted NSCLC.  Dual inhibition of MAT2A and PRMT5 has demonstrated durable tumor regressions in several preclinical MTAP-deleted tumor models, including NSCLC.

KAT6/7

• IDE574 (KAT6/7): a Phase 1 dose escalation trial is underway in solid tumors including breast, prostate, colorectal and lung cancer.  In October, IDEAYA dosed its first patient in a Phase 1 combination cohort of IDE574 with fulvestrant in estrogen receptor positive (ER+) metastatic breast cancer.  IDE574 is a selective, equipotent dual inhibitor of both KAT6 and KAT7 which spares other structurally similar paralogs, including KAT5 and KAT8, which are required for normal cell function. KAT6 and KAT7 are epigenetic modulators of cell identity and lineage commitment programs that are corrupted by oncogenic transformation.

Corporate

• IDEAYA will host an R&D Day on November 16, 2026 in London, United Kingdom to present new preclinical data highlighting IDEAYA's precision medicine pipeline and the opportunity to exploit MTAP/CDKN2A deficiency to greatly enhance the anti-tumor activity of pan-RAS and mutant-specific RAS inhibitors in KRAS-mutant cancers.  Dr. Frank McCormick, Professor of the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco will join members of the management team for the discussion.  Topics will include multiple rational combination strategies to target the underlying tumor heterogeneity and adaptive plasticity in KRAS cancers including PDAC, NSCLC, and colorectal cancer.
• IDEAYA announced the promotion of Dr. Michael White, Ph.D. to President, Research and Development.  Dr. White had served as Chief Scientific Officer at IDEAYA Biosciences since 2021.  Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific academic career of more than 20 years at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program.

Third Quarter 2026 Financial Results

As of September 30, 2026, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.15 billion, compared to $1.24 billion as of June 30, 2026. The decrease was primarily driven by net cash used in operations. IDEAYA's cash runway guidance into 2030 is unchanged based on the current operating plan.

Collaboration revenue for the three months ended September 30, 2026, totaled $10.2 million, compared to $8.9 million for the three months ended June 30, 2026. Collaboration revenue was recognized for the performance obligations satisfied through September 30, 2026 related to the research and development services that are recognized over time under the Servier exclusive license agreement for darovasertib. As of September 30, 2026, the remaining balance for the research and development services performance obligations is $139.8 million related to the clinical development cost reimbursements anticipated under the license agreement that will be recognized as IDEAYA collaboration revenue over time as the research and development services are completed.

Research and development (R&D) expenses for the three months ended September 30, 2026 totaled $121.6 million, compared to $108.7 million for the three months ended June 30, 2026. The increase was primarily driven by higher clinical trial and development costs and personnel-related expenses to support IDEAYA's programs.

General and administrative (G&A) expenses for the three months ended September 30, 2026 totaled $26.3 million, compared to $22.5 million for the three months ended June 30, 2026. The increase was primarily due to higher personnel-related expenses to support company growth and darovasertib commercial preparation activities.

The net loss for the three months ended September 30, 2026, was $125.7 million compared to the net loss of $112.5 million for the three months ended June 30, 2026. Total stock-based compensation expense for the three months ended September 30, 2026, was $17.7 million compared to $16.7 million for the three months ended June 30, 2026.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding darovasertib's development and potential clinical benefits, alone and in combination with crizotinib; the interpretation and potential implications of results from OptimUM-01, OptimUM-02 and OptimUM-09; the timing, conduct and outcome of the FDA's review of the NDA for the darovasertib combination in metastatic uveal melanoma, including under the RTOR program, and the potential approval and commercialization of darovasertib; the design, enrollment, timing and potential results of OptimUM-011; the closure of OptimUM-010, the anticipated cost savings therefrom, and the reallocation of such resources to other programs; the timing of initial clinical data from the global Phase 1/2 trial of IDE849, the planned initiation, design, and endpoints of Phase 3 registrational trials of IDE849, and the potential of IDE849 in SCLC and NEC; the development, timing of data and potential of IDE161, IDE034, IDE892, IDE397 and IDE574, including planned combination cohorts, expansions and trial initiations; IDEAYA's clinical collaborations; IDEAYA's cash runway and the sufficiency of its cash, cash equivalents and marketable securities to fund its operating plan; the possibility of establishing a new standard of care; potential effects on eye preservation and visual outcomes; and future clinical studies and data presentations. These statements reflect current expectations and involve risks and uncertainties, and actual results may differ materially from those expressed or implied. Clinical findings may change with additional follow-up, and early results, small cohorts and subgroup analyses may not predict outcomes in larger or subsequent studies. Factors that could cause actual results to differ include, among others, risks related to drug development, regulatory review and approval, clinical trial site activation and enrollment, manufacturing, reliance on collaborations, commercialization, the sufficiency of IDEAYA's capital resources, changes in IDEAYA's operating plan and macroeconomic conditions. Additional information about risks is available in IDEAYA's most recent Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and its other filings with the Securities and Exchange Commission. IDEAYA does not undertake to update these statements, except as required by law.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

IDEAYA Biosciences, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts)
		Three Months Ended								Nine Months Ended
		September 30, 2026				June 30, 2026				September 30, 2026				September 30, 2025
		(Unaudited)								(Unaudited)
Collaboration revenue		$	10,242			$	8,857			$	25,660			$	207,834
Operating expenses:
Research and development			121,576				108,689				325,991				228,105
General and administrative			26,298				22,459				68,135				44,472
Total operating expenses			147,874				131,148				394,126				272,577
Loss from operations			(137,632)				(122,291)				(368,466)				(64,743)
Interest income and other income, net			11,883				9,839				31,726				34,318
Net loss			(125,749)				(112,452)				(336,740)				(30,425)
Unrealized (losses) gains on marketable securities			(3,214)				(1,176)				(7,151)				1,240
Comprehensive loss		$	(128,963)			$	(113,628)			$	(343,891)			$	(29,185)
Net loss per share    attributable to common    stockholders, basic		$	(1.22)			$	(1.22)			$	(3.56)			$	(0.34)
Weighted-average number of shares   outstanding, basic			102,944,175				92,061,452				94,620,638				88,452,395
Net loss per share    attributable to common    stockholders, diluted		$	(1.22)			$	(1.22)			$	(3.56)			$	(0.34)
Weighted-average number of shares   outstanding, diluted			102,944,175				92,061,452				94,620,638				88,452,395

 

IDEAYA Biosciences, Inc. Condensed Balance Sheet Data (in thousands)
		September 30,				December 31,
		2026				2025
		(Unaudited)
Cash and cash equivalents and short-term and long-term marketable securities		$	1,150,827			$	1,049,685
Total assets			1,216,020				1,109,324
Total liabilities			123,957				86,390
Total liabilities and stockholders' equity		$	1,216,020			$	1,109,324

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-financial-results-for-the-third-quarter-2026-and-provides-a-business-update-302926978.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were IDEAYA's third-quarter 2026 financial results?

IDEAYA reported $10.2 million in collaboration revenue and a $125.7 million net loss for the quarter ended September 30, 2026. The preceding quarter had $8.9 million in collaboration revenue and a $112.5 million net loss. Basic and diluted loss per share remained $1.22.

What is the status of IDEAYA's darovasertib FDA application?

IDEAYA completed its new drug application in Q3 2026 for potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma. The submission was made under the FDA's Real-Time Oncology Review program.

How does IDEAYA plan to support access to neoadjuvant darovasertib after closing OptimUM-010?

IDEAYA plans to submit published OptimUM-09 data to support potential inclusion in clinical practice guidelines. The company intends successful inclusion to provide evidence supporting potential clinical benefit and says it may allow insurer coverage for eligible U.S. patients.

How will IDEAYA's planned IDE849 Phase 3 small cell lung cancer trial be designed?

The planned trial will enroll 400 patients with prior tarlatamab treatment, randomized 1:1 to IDE849 or investigator's choice of therapy. Its primary endpoint for accelerated approval will be response rate assessed by blinded independent central review; median overall survival will be the endpoint for full approval.

What is the design of IDEAYA's OptimUM-011 darovasertib trial?

OptimUM-011 is expected to enroll approximately 450 patients with primary uveal melanoma and increased risk of metastasis, irrespective of HLA status. Patients will be randomized 1:1 to 12 months of darovasertib plus crizotinib or observation. The primary endpoint is relapse-free survival.